View Item 

Show simple item record

Tisagenlecleucel Modelâ Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ T Cells

dc.contributor.authorStein, Andrew M.
dc.contributor.authorGrupp, Stephan A.
dc.contributor.authorLevine, John E.
dc.contributor.authorLaetsch, Theodore W.
dc.contributor.authorPulsipher, Michael A.
dc.contributor.authorBoyer, Michael W.
dc.contributor.authorAugust, Keith J.
dc.contributor.authorLevine, Bruce L.
dc.contributor.authorTomassian, Lori
dc.contributor.authorShah, Sweta
dc.contributor.authorLeung, Mimi
dc.contributor.authorHuang, Pai‐hsi
dc.contributor.authorAwasthi, Rakesh
dc.contributor.authorMueller, Karen Thudium
dc.contributor.authorWood, Patricia A.
dc.contributor.authorJune, Carl H.
dc.date.accessioned2019-05-31T18:28:34Z
dc.date.available2020-07-01T17:47:46Zen
dc.date.issued2019-05
dc.identifier.citationStein, Andrew M.; Grupp, Stephan A.; Levine, John E.; Laetsch, Theodore W.; Pulsipher, Michael A.; Boyer, Michael W.; August, Keith J.; Levine, Bruce L.; Tomassian, Lori; Shah, Sweta; Leung, Mimi; Huang, Pai‐hsi ; Awasthi, Rakesh; Mueller, Karen Thudium; Wood, Patricia A.; June, Carl H. (2019). "Tisagenlecleucel Modelâ Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ T Cells." CPT: Pharmacometrics & Systems Pharmacology 8(5): 285-295.
dc.identifier.issn2163-8306
dc.identifier.issn2163-8306
dc.identifier.urihttps://hdl.handle.net/2027.42/149368
dc.publisherWiley Periodicals, Inc.
dc.titleTisagenlecleucel Modelâ Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ T Cells
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149368/1/psp412388.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149368/2/psp412388-sup-0001-Supinfo.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149368/3/psp412388_am.pdf
dc.identifier.doi10.1002/psp4.12388
dc.identifier.sourceCPT: Pharmacometrics & Systems Pharmacology
dc.identifier.citedreferenceMueller, K.T. et al. CTL019 clinical pharmacology and biopharmaceutics in pediatric patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). Clin. Lymphoma Myeloma Leuk. 17, S261 â S262 ( 2017 ).
dc.identifier.citedreferenceGrupp, S.A. et al. Chimeric antigen receptorâ modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509 â 1518 ( 2013 ).
dc.identifier.citedreferenceBuechner, J. et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis. Clin. Lymphoma Myeloma Leuk. 17, S263 â S264 ( 2017 ).
dc.identifier.citedreferenceMaude, S.L. et al. Tisagenlecleucel in children and young adults with Bâ cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439 â 448 ( 2018 ).
dc.identifier.citedreferenceDe Boer, R.J. & Perelson, A.S. Quantifying T lymphocyte turnover. J. Theor. Biol. 327, 45 â 87 ( 2013 ).
dc.identifier.citedreferenceDe Boer, R.J., Oprea, M., Antia, R., Muraliâ Krishna, K., Ahmed, R. & Perelson, A.S. Recruitment times, proliferation, and apoptosis rates during the CD8(+) Tâ cell response to lymphocytic choriomeningitis virus. J. Virol. 75, 10663 â 10669 ( 2001 ).
dc.identifier.citedreferenceKalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 ( 2011 ).
dc.identifier.citedreferenceMueller, K.T. et al. Cellular kinetics of CTL019 in relapsed/refractory Bâ cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317 â 2325 ( 2017 ).
dc.identifier.citedreferenceLe, R.Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cellâ induced severe or lifeâ threatening cytokine release syndrome. Oncologist 23, 943 â 947 ( 2018 ).
dc.identifier.citedreferenceFauci, A.S., Dale, D.C. & Balow, J.E. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann. Intern. Med. 84, 304 â 315 ( 1976 ).
dc.identifier.citedreferenceLanza, L. et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin. Exp. Immunol. 103, 482 â 490 ( 1996 ).
dc.identifier.citedreferenceMaude, SL et al. Sustained remissions with CD19â specific chimeric antigen receptor (CAR)â modified T cells in children with relapsed/refractory ALL. J. Clin. Oncol. 34 ( 15 suppl. ), 3011 ( 2016 ).
dc.identifier.citedreferenceJanetzki, S. et al. â MIATAâ â minimal information about T cell assays. Immunity 31, 527 â 528 ( 2009 ).
dc.identifier.citedreferenceCrotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L. & Ahmed, R. Cutting edge: longâ term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969 â 4973 ( 2003 ).
dc.identifier.citedreferencePorter, D.L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 ( 2015 ).
dc.identifier.citedreferenceScholler, J. et al. Decadeâ long safety and function of retroviralâ modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 ( 2012 ).
dc.identifier.citedreferenceLee, D.W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188 â 195 ( 2014 ).
dc.identifier.citedreferenceBranford, S. et al. Desirable performance characteristics for BCRâ ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112, 3330 â 3338 ( 2008 ).
dc.identifier.citedreferenceHu, C., Zhang, J. & Zhou, H. Confirmatory analysis for phase III population pharmacokinetics. Pharm. Stat. 10, 14 â 26 ( 2011 ).
dc.identifier.citedreferenceFinal report, pharmacometric analysisâ Kymriah (tisagenlecleucel). < https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm >. Accessed September 25, 2018.
dc.identifier.citedreferencePharmacometric reviewâ Yescarta (axicabtagene ciloleucel). < https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm >. Accessed September 25, 2018.
dc.identifier.citedreferenceSmith, C.J., Quinn, M. & Snyder, C.M. CMVâ specific CD8 T cell differentiation and localization: implications for adoptive therapies. Front. Immunol. 7, 352 ( 2016 ).
dc.identifier.citedreferenceMaude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507 â 1517 ( 2014 ).
dc.identifier.citedreferenceMueller, K.T. et al. Cellular kinetics of chimeric antigen receptor T cells (CTL019) in patients with relapsed/refractory CD19+ leukemia. Blood 128, 220 ( 2016 ).
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
psp412388.pdf
Size:
464.1KB
Format:
PDF
View/Open
Name:
psp412388-sup-0001-Supinfo.pdf
Size:
1.363MB
Format:
PDF
View/Open
Name:
psp412388_am.pdf
Size:
738.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.